Vaccination with Dendritic Cell Myeloma Fusions in Conjuction with Stem Cell Transplantation and PD-1 Blockade

Abstract

In this project, we conducted a clinical trial in which patients with multiple myeloma were treated with an anti-PD1 antibody (CT-011) alone (Cohort 1) and in conjunction with a dendritic cell/myeloma fusion cell vaccine (Cohort 2) following autologous transplantation. The goal ofthe project was to determine the effect of CT-011 alone, and in conjunction with a DC/myeloma fusion cell vaccine, to stimulate effective anti-tumor immunity and disease response.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Jul 01, 2015
Accession Number
AD1003914

Entities

People

  • David Avigan

Organizations

  • Beth Israel Deaconess Medical Center

Tags

DTIC Thesaurus Topics

  • Antibodies
  • Blood
  • Cells
  • Clinical Trials
  • Drug Therapy
  • Hematologic Diseases
  • Immunity
  • Immunotherapy
  • Lymphatic Diseases
  • Lymphocytes
  • Medical Personnel
  • Pain
  • Stem Cells
  • Therapy
  • Transplants
  • Vaccination
  • Vaccines

Fields of Study

  • Biology
  • Medicine

Readers

  • Immunology
  • Oncology

Technology Areas

  • Biotechnology
  • Biotechnology - Cancer Biotech